These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 21886702)

  • 1. Rituximab therapy of recalcitrant bullous dermatoses.
    Wollina U; Koch A; Hansel G
    J Dermatol Case Rep; 2008 Mar; 2(1):4-7. PubMed ID: 21886702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bullous autoimmune dermatoses.
    Hofmann SC; Juratli HA; Eming R
    J Dtsch Dermatol Ges; 2018 Nov; 16(11):1339-1358. PubMed ID: 30395395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pemphigus Vulgaris and Bullous Pemphigoid: Update on Diagnosis and Treatment.
    Di Lernia V; Casanova DM; Goldust M; Ricci C
    Dermatol Pract Concept; 2020 Jul; 10(3):e2020050. PubMed ID: 32642305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients.
    Kasperkiewicz M; Shimanovich I; Ludwig RJ; Rose C; Zillikens D; Schmidt E
    J Am Acad Dermatol; 2011 Sep; 65(3):552-558. PubMed ID: 21641080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and Safety of Rituximab in Recalcitrant Pemphigoid Diseases.
    Lamberts A; Euverman HI; Terra JB; Jonkman MF; Horváth B
    Front Immunol; 2018; 9():248. PubMed ID: 29520266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual diagnosis of Pemphigus and pemphigoid. Retrospective review of thirty cases in the literature.
    Sami N; Ahmed AR
    Dermatology; 2001; 202(4):293-301. PubMed ID: 11455140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab therapy for refractory autoimmune bullous diseases: A multicenter, open-label, single-arm, phase 1/2 study on 10 Japanese patients.
    Kurihara Y; Yamagami J; Funakoshi T; Ishii M; Miyamoto J; Fujio Y; Kakuta R; Tanikawa A; Aoyama Y; Iwatsuki K; Ishii N; Hashimoto T; Nishie W; Shimizu H; Kouyama K; Amagai M
    J Dermatol; 2019 Feb; 46(2):124-130. PubMed ID: 30585649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab in autoimmune pemphigoid diseases: Indications, optimized regimens, and practice gaps.
    Thomas RM; Colon A; Motaparthi K
    Clin Dermatol; 2020; 38(3):384-396. PubMed ID: 32563354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. World Workshop of Oral Medicine VII: A systematic review of immunobiologic therapy for oral manifestations of pemphigoid and pemphigus.
    Mays JW; Carey BP; Posey R; Gueiros LA; France K; Setterfield J; Woo SB; Sollecito TP; Culton D; Payne AS; Greenberg MS; De Rossi S
    Oral Dis; 2019 Jun; 25 Suppl 1(Suppl 1):111-121. PubMed ID: 31140696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bullous Diseases.
    Corbaux C; Joly P
    Curr Probl Dermatol; 2018; 53():64-69. PubMed ID: 29131038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Case of Severe Bullous Dermatitis With Mixed Bullous Pemphigoid and Pemphigus Vulgaris Cutaneous Manifestations.
    Burns RD; Vetos D; Muraga R
    Cureus; 2021 Dec; 13(12):e20433. PubMed ID: 35047270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective analysis of the long-term therapeutic effectiveness and safety profile of rituximab in the treatment of mucous membrane pemphigoid in a German university center between 2008 and 2019.
    Bamberger F; König IR; Gola D; Zillikens D; Sadik CD
    Front Immunol; 2023; 14():1180150. PubMed ID: 37143653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab in Mucous Membrane Pemphigoid: A Monocentric Retrospective Study in 10 Patients with Severe/Refractory Disease.
    Baffa ME; Corrà A; Maglie R; Mariotti EB; Montefusco F; Pipitò C; Senatore S; Quintarelli L; Caproni M; Antiga E
    J Clin Med; 2022 Jul; 11(14):. PubMed ID: 35887866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Geographic variations in epidemiology of two autoimmune bullous diseases: pemphigus and bullous pemphigoid.
    Alpsoy E; Akman-Karakas A; Uzun S
    Arch Dermatol Res; 2015 May; 307(4):291-8. PubMed ID: 25589418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful Treatment of a Bullous Pemphigoid Patient with Rituximab Who Was Refractory to Corticosteroid and Omalizumab Treatments.
    Bilgiç Temel A; Bassorgun CI; Akman-Karakaş A; Alpsoy E; Uzun S
    Case Rep Dermatol; 2017; 9(1):38-44. PubMed ID: 28413387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral lesions in patients with pemphigus vulgaris and bullous pemphigoid.
    Budimir J; Mihić LL; Situm M; Bulat V; Persić S; Tomljanović-Veselski M
    Acta Clin Croat; 2008 Mar; 47(1):13-8. PubMed ID: 18714642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Autoimmune blistering diseases].
    Duvert-Lehembre S; Joly P
    Rev Med Interne; 2014 Mar; 35(3):166-73. PubMed ID: 23747156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination Therapy of Plasma Exchange and Rituximab to Treat Cicatricial Pemphigoid and Bullous Pemphigoid.
    Kunadia A; Sami N
    Cureus; 2021 Nov; 13(11):e19932. PubMed ID: 34984113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful adjuvant treatment of recalcitrant mucous membrane pemphigoid with anti-CD20 antibody rituximab.
    Taverna JA; Lerner A; Bhawan J; Demierre MF
    J Drugs Dermatol; 2007 Jul; 6(7):731-2. PubMed ID: 17763598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consensus on the treatment of autoimmune bullous dermatoses: bullous pemphigoid, mucous membrane pemphigoid and epidermolysis bullosa acquisita - Brazilian Society of Dermatology.
    Santi CG; Gripp AC; Roselino AM; Mello DS; Gordilho JO; Marsillac PF; Porro AM
    An Bras Dermatol; 2019 Apr; 94(2 Suppl 1):33-47. PubMed ID: 31166405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.